SavedAdd your journal

Journals / Dicle Tıp Dergisi / 2026 / Cilt: 46 Sayı: 3

Akciğer kanserinin tedavisinde periferiknöropati; Önemli bir komorbidite

Şenay Aydın0000-0003-4460-9056
Cengiz Özdemir0000-0002-9816-8885
Suna Aşkın Turan0000-0002-2397-0179
Yusuf Başer0000-0003-3817-3823
Murat Kıyık0000-0001-8737-1418
Pages
505–514
Publication Date
2019-09-16
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Bu çalışmada kemoterapi tedavisi alan ve periferiknöropati gelişen akciğer kanseri tanılı hastalarda klinik semptomlar ve elektrofizyolojik bulguların değerlendirilmesi amaçlandı.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amaç: Klinik pratiğimizde akciğer kanseri tedavisinde uygulanan kemoterapi rejimlerine bağlı gelişen periferiknöropatiler sık gözlenmektedir.
📊
Key Findings & Data:Amaç: Klinik pratiğimizde akciğer kanseri tedavisinde uygulanan kemoterapi rejimlerine bağlı gelişen periferiknöropatiler sık gözlenmektedir.
💡
Conclusion & Impact:Bu çalışmada kemoterapi tedavisi alan ve periferiknöropati gelişen akciğer kanseri tanılı hastalarda klinik semptomlar ve elektrofizyolojik bulguların değerlendirilmesi amaçlandı.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Akciğer kanseri · elektromiyografi · duyusal semptomlar

Özet

Amaç: Klinik pratiğimizde akciğer kanseri tedavisinde uygulanan kemoterapi rejimlerine bağlı gelişen periferiknöropatiler sık gözlenmektedir. Bu çalışmada kemoterapi tedavisi alan ve periferiknöropati gelişen akciğer kanseri tanılı hastalarda klinik semptomlar ve elektrofizyolojik bulguların değerlendirilmesi amaçlandı.

🔖

Cite This Article

Aydın, Ş., Özdemir, C., Turan, S. A., Başer, Y., Kıyık, M. (2019). Akciğer kanserinin tedavisinde periferiknöropati; Önemli bir komorbidite. Dicle Tıp Dergisi, Cilt: 46 Sayı: 3, 505–514. https://doi.org/10.5798/dicletip.620534

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (29)

  1. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002; 249: 9-17.
  2. Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol.2013; 18: 4: 156.
  3. Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014; 6: 135–47.
  4. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy‐induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin. 2013; 63: 419–37.
  5. Al-Atiyyat N, Obaid A. Management of peripheral neuropathy induced by chemotherapy in adults with cancer: a review. Int J Palliat Nurs. 2017 Jan 2; 23: 13-7.
  6. Kerckhove N, Pereira B, Pezet D, Balayssac D. Clinicalassessment of new antineuropathic strategies for chemotherapy-induced peripheral neuropathy: pain should not be the principal endpoint. Pain. 2017; 158: 180–2.
  7. Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain. 2007 Apr; 8: 296-306.
  8. Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs. 2007 Aug; 23: 162-73.
  9. Gutierrez-Gutierrez G, Sereno M, Miralles A, Casado-Saenz E, Gutierrez Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin. Transl. Oncol. 2010; 12: 81-91.
  10. Seretny M, Currie GL, Sena ES, et all. Incidence, prevalence, and predictors of chemotherapyinduced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014; 155: 2461–70.
  11. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004 May; 109: 132-42.
  12. Johnson C, Pankratz VS, Velazquez AI, et all. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J. Neurol. Sci. 2015; 349: 124–8.
  13. Paternostro-Sluga T, Grim-Stieger M, Posch M, et all. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med. 2008 Aug; 40: 665-71.
  14. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005; 32: 51–60.
  15. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr. 1993; 15: 107–15.
  16. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with pacliaxel. J Pain 2009; 10: 1146-50.
  17. Kolb NA, Smith AG, Singleton JR, et all. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurol. 2016; Jul 1; 73: 860-6.
  18. Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ. Will my patient fall? JAMA. 2007; 297: 77-86.
  19. Strumberg D, Brugge S, Korn MW, et all. Evaluation of long-term toxicity in patients after cisplatinbased chemotherapy for non seminomatous testicular cancer. Ann. Oncol.2002; 13: 229–36.
  20. Hile ES, Fitzgerald GK, Studenski SA. Persistent mobility disability after neurotoxic chemotherapy. Phys Ther. 2010 Nov; 90: 1649-57.
  21. Gutiérrez-Gutiérrez G, Sereno M, Miralles A, Casado-Sáenz E, Gutiérrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010 Feb; 12: 81-91.
  22. Fernandes R, Mazzarello S, Hutton B, et all. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support. Care Cancer. 2016; 24: 3633–50.
  23. Loprinzi CL, Maddocks-Christianson K, Wolf SL, et all. The Paclitaxel acute pain syndrome:sensitization of nociceptors as the putative mechanism. Cancer J. 2007; 13: 399–403.
  24. Loprinzi CL, Reeves BN, Dakhil SR, et all. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011; 29: 1472–8.
  25. Amptoulach, S., and Tsavaris, N. Neurotoxicity caused by the treatment with platinum analogues. Chemother. Res. Pract. 2011; 2011: 843019.
  26. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008; 44: 1507–15.
  27. Monfort SM, Pan X, Patrick R, et all. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat. 2017 Jul; 164: 69-77.
  28. Koike H, Tanaka F, Sobue G. Paraneoplastic neuropathy: wide-ranging clinicopathological manifestations. Curr Opin Neurol. 2011; 24: 504-10.
  29. Raspotnig M, Vedeler C, Storstein A. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies. J Neurol Sci. 2015; 15: 348: 41-5.